ZEN Graphene’s Dr Francis Dube on the ZENGuardTM enhanced surgical masks and the development of a new fuel additive
In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Francis Dube, Executive Chairman of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about ZEN’s recent milestones including the successful inhalation safety testing of the ZENGuardTM enhanced surgical masks and the development of a new fuel additive.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Dube starts by explaining the impact of the ZENGuardTM enhanced surgical masks and submission to Health Canada news release. He discusses how their market is with the medical industry and how this demand will only grow.
Equally as interesting to host Tracy was the potential to attract ESG funds with the new fuel additive announcement. Francis explains that ZEN has developed a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing. He states that “If we can make diesel fuel 10-20% better we are going to have a significant impact on the amount of emissions…we think we can make a difference from an environmental standpoint.”
To watch the full interview, click here
About ZEN Graphene Solutions Ltd.
ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing ZEN Guard TM , a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN’s Albany Pure TM Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.
To learn more about ZEN Graphene Solutions Ltd., click here
Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please email firstname.lastname@example.org.